Clinical Sciences

A new type of cell therapy to treat patients with liver scarring, or cirrhosis, shows promise of being the first medical treatment for this common and lethal condition.

University of Edinburgh spinout eoSurgical has announced it has been acquired by Limbs & Things – a UK-based company that manufactures medical task trainers and simulators.

Global pharmaceutical company Eisai, Bill Gates’ private office Gates Ventures, Health Data Research UK (HDR UK), medical research not-for-profit LifeArc and the University of Edinburgh have announced a new two-year collaborative research agreement that aims to transform care for people living with dementia.

Scottish scientists were at the SynBioBeta global life sciences conference in San Francisco in May to showcase world-class research and expertise in an area of crucial importance to the economy. We have much to be proud of, writesDr Susan Bodie, Head of Business Development for the College of Medicine and Veterinary Medicine at Edinburgh Innovations

Here in Scotland, we currently have a confluence of factors – data capacity, clinical and academic expertise, and technology – that put us in pole position to translate our excellent liver disease research and to develop the innovative new treatments we need, writes Dr Prakash Ramachandran, MRC Senior Clinical Fellow and Consultant Hepatologist at the University of Edinburgh...

An algorithm developed using artificial intelligence could soon be used by doctors to diagnose heart attacks with better speed and accuracy than ever before, according to new research from the University of Edinburgh, funded by charity the British Heart Foundation and the UK’s National Institute for Health and Care Research, and published today in Nature Medicine.

Endometriosis is a chronic inflammatory pain condition that affects one in ten females and those assigned female at birth. It costs the UK economy £8.2 billion a year in treatment, loss of work and healthcare costs.

Emerging biotech company Stimuliver, co-founded by the University of Edinburgh’s Professor David Hay, has announced financing of £1.7m for its regenerative stem cell therapy to treat acute and chronic liver diseases.